|Bid||80.79 x 600|
|Ask||80.81 x 400|
|Day's Range||80.52 - 82.47|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.77|
|Earnings Date||Oct 26, 2017|
|Dividend & Yield||2.08 (2.56%)|
|1y Target Est||84.20|
Verizon, American Express, Nike, Blue Apron and Gilead Sciences are among the stocks to watch.
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
Gilead jumped early Thursday after the FDA approved its CAR-T drug, dubbed Yescarta, to treat Non-Hodgkin lymphoma.
The Dow looks set to drop around 100 points as U.S. markets look to follow international stocks lower this morning. S&P 500 futures have fallen 0.5% , while Dow Jones Industrial Average futures have declined ...
Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics.
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration has granted regular approval to Yescarta™ , the first chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell ...